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9-(trans-2',trans-3'-Dihydroxycyclopent-4'-enyl)-adenine (compound 1) and -3-deazaadenine (compound 2),
which are specific inhibitors of S-adenosylhomocysteine (AdoHcy) hydrolase, were reported earlier by our
laboratory (M. Hasobe, J. G. McKee, D. R. Borcherding, and R. T. Borchardt, Antimicrob. Agents
Chemother. 31:1849-1851, 1987) to have anti-vaccinia virus activity with reduced murine L-929 cell toxicity
compared with the prototype compound neplanocin A. In this study, we showed that the antiviral and cytotoxic
effects of compounds 1 and 2 can be related to intracellular concentrations of AdoHcy, which are elevated in
cells treated with these inhibitors of AdoHcy hydrolase. For example, concentrations of analogs 1 and 2 that
produce 50% inhibition of vaccinia virus replication caused only slight elevations in intracellular levels of
AdoHcy (from 50 [controls] to 100 to 125 [drug-treated cells] pmol/mg of protein) and elevations in the ratios
of AdoHcy/S-adenosylmethionine (from 0.05 to 0.1 [controls] to 0.15 to 0.19 [drug-treated cells]). In contrast
to the extreme susceptibility of virus replication to slight elevations in intracellular AdoHcy, cell viability was
quite tolerant to higher levels of this metabolite. For example, concentrations of analogs 1 and 2 that produced
50% inhibition of L-929 cell replication caused significant increases in intracellular levels of AdoHcy (to 825 to
950 pmol/mg of protein) and elevations in AdoHcy/S-adenosylmethionine ratios (approximately 1.3). These
data make it possible to assign a therapeutic index of 7 to 8 to these compounds on the basis of the comparison
of intracellular levels of AdoHcy that caused 50% inhibition of vaccinia virus replication with those that caused
50% inhibition of L-929 cell replication.
S-Adenosylhomocysteine (AdoHcy) hydrolase (EC 3.3.1.
1) has become an attractive target for the design of antiviral
agents (7, 19). This cellular enzyme catalyzes the hydrolysis
of AdoHcy to adenosine and homocysteine, thus maintain-
ing low cellular concentrations of this product inhibitor of
S-adenosylmethionine (AdoMet)-dependent methylations
(31). Inhibition of cellular AdoHcy hydrolase, however,
results in intracellular accumulation of AdoHcy, causing a
significant increase in the intracellular AdoHcy/AdoMet
ratio and subsequent inhibition of virus replication (3, 18).
The inhibition of viral AdoMet-dependent mRNA methyla-
tions caused by elevated cellular levels of AdoHcy has been
proposed by us to be the molecular mechanism by which
AdoHcy hydrolase inhibitors, such as neplanocin A and
adenosine dialdehyde, inhibit vaccinia virus replication in
murine L-929 cells (17-19). Ransohoff et al. (28) have re-
ported direct evidence showing that inhibition of influenza
virus replication in CHO cells by neplanocin A is due at least
in part to impaired recognition of undermethylated cellular
mRNA cap structures by the influenza virus polymerase
complex.
Neplanocin A, like many other AdoHcy hydrolase inhib-
itors, also exhibits considerable cellular toxicity, which
limits its utility as an antiviral agent (6). The cytotoxic effects
of neplanocin A are mediated at least in part through its
phosphorylation by adenosine kinase and subsequent con-
version of neplanocin A triphosphate to S-neplanocylme-
thionine (9, 10, 14, 15, 20, 21). Recently, our laboratory
described the synthesis (4) and biological activity (12, 13, 19,
25) of 9-(trans-2',trans-3'-dihydroxycyclopent-4'-enyl)-ade-
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nine (Fig. 1, compound 1) and -3-deazaadenine (Fig. 1,
compound 2), which are neplanocin A analogs that retain
inhibitory activity toward AdoHcy hydrolase but are devoid
of substrate activity for adenosine kinase. These carbocyclic
nucleosides inhibit vaccinia virus replication in mouse L-929
cells, but their cytotoxicity is reduced compared with that of
neplanocin A (12). These data confirm earlier studies by De
Clercq and Cools (8) which showed that AdoHcy hydrolase
is the molecular target which mediates the antiviral effects of
neplanocin A. These data also confirmed earlier work by
Glazer et al. (9, 11) with 3-deazaneplanocin A which showed
that transformation by cellular adenosine kinase mediates in
part the cytotoxic properties of neplanocin A.
However, since synthetic analogs 1 and 2, which are pure
inhibitors of AdoHcy hydrolase, still exhibit some toxicity in
murine L-929 cells (12), we were interested in determining
whether a relationship existed between this cellular toxicity
and the elevated intracellular concentrations of AdoHcy. In
this study, we showed that the antiviral and cytotoxic effects
of compounds 1 and 2 can be related to elevations in the
intracellular concentrations of AdoHcy and that it is possible
to define a therapeutic index for these analogs on the basis of
the intracellular levels of AdoHcy needed to inhibit virus
replication and the intracellular levels of AdoHcy needed to
produce cellular toxicity.
MATERIALS AND METHODS
Materials. The following standard chemicals and supplies
were purchased from commercial suppliers: Waymouth 752/
1 (low-calcium) medium (for spinner culture), Waymouth
MB 752/1 medium (for dish culture), and bovine calf serum
(Hazleton Research Products, Denver, Pa.); 24-well (13-mm
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FIG. 1. Structures of neplanocin A and analogs 1 and 2.
diameter) or 6-well (30-mm diameter) multiculture dishes
(Costar, Cambridge, Mass.); cell culture dishes (60-mm
diameter; Corning Glass Works, Corning, N.Y.); monobasic
sodium phosphate (high-pressure liquid chromatography
[HPLC] grade), 1-heptanesulfonic acid sodium salt (HPLC
grade; Fisher Scientific Co., Pittsburgh, Pa.); Zorbax C-8
reversed-phase HPLC column (Du Pont Co., Wilmington,
Del.); guanidine thiocyanate (Eastman Kodak Co., Roches-
ter, N.Y.); oligo(dT)-cellulose (Pharmacia Biotechnology
Products, Piscataway, N.J.); [methyl-3H]methionine (80 Ci/
mmol; Amersham Corp., Arlington Heights, Ill.);
['4C]uridine (517.5 mCi/mmol; Dupont, NEN Research
Products, Boston, Mass.); 1,1,2-trichlorotrifluoroethane (Al-
drich Chemical Co., Inc., Milwaukee, Wis.); tri-n-octyl-
amine (Sigma Chemical Co., St. Louis, Mo.); ammonium
dihydrogen phosphate (HPLC grade; Fisher Scientific); and
a Partisil-10 SAX column (4.6 by 250 mm; Whatman, Inc.,
Clifton, N.J.). Neplanocin A was kindly donated by Toyo
Jozo Co., Shizuoka, Japan. Compounds 1 and 2 were
synthesized as described earlier by us (4).
Cell culture. Stock cultures of clone 929 mouse cells,
strain L (Earle), were grown in suspension at 37°C in
Waymouth 752/1 medium supplemented with 4% bovine calf
serum and 70 jig of gentamicin per ml as described previ-
ously (3, 16). Experimental cultures of L-929 cells plated in
tissue culture dishes or multiculture plates were grown in
Waymouth MB 752/1 medium containing 2% calf serum.
Determination of intracellular levels of AdoHcy and
AdoMet. Cultures of mouse L-929 cells (approximately 3x
106/60-mm-diameter dish) were incubated at 37°C with Way-
mouth MB 752/1 medium containing 2% calf serum with or
without compound 1 or 2. Cells were removed from the
culture dishes at various times by trypsin treatment and
lysed in 100,il of 0.25 N perchloric acid by vigorous
vortexing and rapid freezing on dry ice-acetone. The sam-
ples were stored at -70°C before analysis. Under these
conditions of storage, AdoMet and AdoHcy were stable
indefinitely. In preparation for HPLC analysis, the samples
were rapidly thawed and the cell debris was removed by
centrifugation in an Eppendorf microcentrifuge (12,400 rpm,
1 min). The supernatant (100,ul) was injected into a Perkin-
Elmer series 3HPLC equipped with a Zorbax C-8 reverse-
phase column (25 cm by 4.6 mm). AdoHcy and AdoMet
were separated by a two-step gradient program at a flow rate
of 1.0 mlmin. Solvent A was acetonitrile, and solvent B was
50 mM sodium phosphate (pH 3.2)-10 mM heptanesulfonic
acid. The program was 5 to 20% solvent A for 15 min and 20
to 25% solv>ent A for 10 min. Quantitation was by A254.
Anti-vaccinia virus assay. Experimental cultures for the
anti-vaccinia virus assay were plated in 24-well multiculture
plates and grown in Waymouth MB 752/1 medium containing
2% calf serum. Nearly confluent cell monolayers were
infected with vaccinia virus at about 200 PFU per well. After
a 60-min virus adsorption period, the viral inoculum was
diluted by addition of culture medium and then completely
removed by aspiration. Immediately after infection, each
well containing a cell monolayer was overlaid with medium
(400 FU) containing 0.1% methylcellulose and 2% calf serum
to which was added medium (100 ,ul) containing test com-
pounds in serial dilutions in increments of 0.5 order of
magnitude. After incubation for 48 h at 37°C, cultures were
washed with phosphate-buffered saline and stained with
0.1% crystal violet. The plaque number was then counted
under a microscope. The experiments were conducted in
duplicate, and the data are expressed as IC50s (concentra-
tions needed to produce 50% inhibition of plaque formation).
Murine L-929 cell toxicity assay. The effects of analogs 1
and 2 on cell growth were determined by trypan blue staining
of L-929 cells grown in various concentrations of the test
compounds. L-929 cells were plated at 4.5 x 105 per dish
(30-mm diameter) and grown in Waymouth MB 752/1 me-
dium containing 2% calf serum. After 6 h of incubation, the
cells were fed with fresh medium with or without the test
compounds. After incubation for 72 h, the cells were dis-
persed by trypsin treatment and suspended in phosphate-
buffered saline containing 0.04% trypan blue. Viable cells
were counted with a hemacytometer. The experiments were
conducted in triplicate, and the data are expressed as ID50s
(concentrations needed to produce 50% inhibition of cell
growth).
Cytoplasmic poly(A)+ mRNA methylation in vaccinia virus-
infected L-929 cells. L-929 cells in spinner culture (6 x 105
cells per ml in 550 ml) were grown in Waymouth 752/1
medium lacking methionine and containing 2% dialyzed calf
serum with or without analog 1. After incubation for 18 h in
suspension at 37°C, the cells were precipitated by centrifu-
gation, the supernatant was aspirated, and the concentrated
cells (100 ml per bottle) treated with analog 1 were infected
with vaccinia virus (multiplicity of infections, 15) and then
treated with cycloheximide (final concentration, 100,ug/ml).
After 1 h of incubation, adenosine (20FLM) and guanosine (10
,uM) were simultaneously added, and 1 h later the cells were
pulse-labeled with [methyl-3H]methionine (10,uCi/ml) and
[14C]uridine (0.5,uCi/ml). After 3 h of labeling, the infected
cells were harvested by centrifugation and washed with
phosphate-buffered saline. The total cytoplasmic RNA was
then prepared by the guanidine isothiocyanate method (at
pH 9) (22). The total cytoplasmic RNA was fractionated to
poly(A)+ mRNA by oligo(dT)-cellulose affinity chromatog-
raphy (22).
Separation and quantitation of rNTPs by HPLC. Cultures
of L-929 cells (approximately 6 x 106/60-mm-diameter dish)
were incubated at 37°C with Waymouth MB 752/1 medium
containing 2% calf serum with or without 10,uM compound
1 or 2 or neplanocin A. After incubation for 6 h, the cells
were washed with cold phosphate-buffered saline, harvested
into a microcentrifuge tube with trypsin treatment, and then
centrifuged at 14,000 rpm for 1 min in an Eppendorf micro-
centrifuge. The cell pellet was suspended in 120 pl of cold
trichloroacetic acid solution (final concentration, 0.3 M) and
vortexed vigorously for 15 min at 40C. After centrifugation
(14,000 rpm for 1 min), the acid-soluble fraction was sepa-
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rated and treated with cold Freon (1,1,2-trichlorotrifluoro-
ethane) containing 0.5 M tri-n-octylamine for a few minutes
at 4°C with gentle vortexing (30). The mixture was then
centrifuged (14,000 rpm for 1 min), and the aqueous fraction
was separated and analyzed with the HPLC system de-
scribed above under Determination of intracellular levels of
AdoHcy and AdoMet, except for a Partisil-10 SAX column
(4.6 mm by 25 cm). Ribonucleoside 5'-triphosphates (rNTPs;
CTP, UTP, ATP, and GTP) were separated by elution with
0.4 M NH4H2PO4 (pH 3.30)-CH3CN (10:1) at a flow rate of
2 ml/min and quantitated at 254 nm (30).
RESULTS
Intracellular AdoHcy levels and AdoHcy/AdoMet ratios in
murine L-929 cells treated with analogs 1 and 2. Treatment of
murine L-929 cells with analog 1 caused concentration-
dependent accumulation of intracellular AdoHcy (Fig. 2A).
The time-dependent profile for accumulation of AdoHcy in
cells treated with analog 1 was characterized by an accumu-
lation phase (up to about 12 h), followed by a plateau phase
(from 12 to 72 h) (Fig. 2A). In contrast, the intracellular
content of AdoMet in L-929 cells treated with analog 1
increased in the first 2 h, after which it was somewhat
variable before stabilizing at 72 h (Fig. 2B). Thus, the profile
of the AdoHcy/AdoMet ratios, which is shown in Fig. 2C,
exhibited an accumulation phase (up to 24 h) followed by a
plateau phase (from 24 to 72 h). Data similar to those shown
in Fig. 2 for analog 1 were also obtained with analog 2 (data
not shown). Increases in both AdoHcy levels and AdoHcy/
AdoMet ratios were observed in cells treated for 24 h with
analog 1 and 2 concentrations as low as 0.3 and 1 ,uM,
respectively (Fig. 3).
Relationship between elevated intracellular AdoHcy levels
(and AdoHcy/AdoMet ratios) and anti-vaccinia virus activity
and inhibition of cell growth. The anti-vaccinia virus activi-
ties of compounds 1 and 2 were evaluated by measuring the
inhibition of virus plaque formation during 48 h of exposure
to the drug. The IC50s of compounds 1 and 2 were deter-
mined to be 0.28 and 0.95 ,uM, respectively (Fig. 3).
The effects of analogs 1 and 2 on L-929 cell growth were
evaluated by determnination of ID50s after exposure to the
drugs for 72 h. The ID50s of compounds 1 and 2 were
determined to be 17 and 56 jiM, respectively (Fig. 4). Thus,
the antiviral indexes (ID5JIC50) were calculated to be 61 and
59 for analogs 1 and 2, respectively.
The IC50s caused only a slight elevation in the AdoHcy/
AdoMet ratios (Fig. 3; Table 1) compared with the ID50s
(Fig. 4; Table 1). At the IC50s of compounds 1 and 2, the
intracellular AdoHcy levels were approximately 100 to 125
pmol/mg of protein and the AdoHcy/AdoMet ratios were
approximately 0.15 to 0.19 (Table 1), whereas at the ID50s of
compounds 1 and 2 the intracellular levels of AdoHcy were
approximately 825 to 950 pmol/mg of protein and the
AdoHcy/AdoMet ratios were approximately 1.3 (Table 1).
Thus, cytotoxicity was observed at cellular concentrations
of AdoHcy seven to eight times the concentration needed to
inhibit virus replication.
Effects of analog 1 on methylation of poly(A)+ RNA isolated
from drug-treated, virus-infected L-929 cells. To determine
whether analog 1 at concentrations (0.03 to 3 ,uM) which
produce 20 to 90% inhibition of virus replication causes
inhibition of the methylation of poly(A)+ RNA, drug-
treated, virus-infected cells were pulse-labeled with [methyl-
3H]methionine and [14C]uridine, the total cytoplasmic RNA
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FIG. 2. Intracellular AdoHcy and AdoMet contents and
AdoHcy/AdoMet ratios in murine L-929 cells treated with various
concentrations of analog 1. Cultures of mouse L-929 cells (approx-
imately 3 x 106/60-mm dish) were incubated with Waymouth
MB752/1 medium containing 2% calf serum with or without com-
pound 1. Symbols: 0, 0 ,uM; 0, 0.1 ,uM; A, 1 ,uM; A, 3.2 ,uM; 0,
10 FM; M, 32 ,uM. At various times, the cells were harvested by
trypsin treatment and lysed with 0.25 N perchloric acid and the
AdoHcy (A) and AdoMet (B) levels were determined by HPLC as
described in Materials and Methods. The AdoHcy/AdoMet ratios
calculated from the data shown in panels A and B are presented in
panel C. The data are averages of duplicate assays.
RNase inhibitor (vanadyl nucleoside complex) (22), ahd
poly(A)+ RNA was purified by oligo(dT)-cellulose chroma-
tography (22). Treatment of virus-infected cells with analog
1 suppressed the methylation of poly(A)+ RNA (Table 2,
experiment 1). The 3H/'4C ratios in poly(A)+ RNA isolated
from cells treated with analog 1 at 0.03 to 3.0 ,uM were 26 to
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FIG. 3. Relationship between anti-vaccinia virus activity and
AdoHcy/AdoMet ratios in murine L-929 cells treated with various
concentrations of analogs 1 and 2. Nearly confluent cell monolayers
were infected with vaccinia virus at about 200 PFU per well as
described in Materials and Methods. After a 60-min virus adsorption
period, the viral inoculum was removed and the cells were overlaid
with medium containing 0.1% methylcellulose with or without
analog 1 (0) or 2 (0). After 48 h of incubation, the cultures were
washed and stained and the plaques were counted as described in
Materials and Methods. The data are averages of three separate
assays done in duplicate. AdoHcy/AdoMet ratios (A, analog 1; A,
analog 2) were determined after 24 h as described in the legend to
Fig. 2.
37% lower than those of poly(A)+ RNA isolated from
non-drug-treated, virus-infected cells (control samples).
It should be noted that the extent of incorporation of
[methyl-3H]methionine and [14C]uridine into poly(A)+ RNA
and the yield of poly(A)+ RNA by the guanidine isothiocy-
anate isolation method and the oligo(dT)-cellulose chroma-
tography method varied from experiment to experiment. The
reproducibility of the data observed in experiment 1 (Table
2) was verified by repeating the experiments with slightly
different concentrations of analog 1 (Table 2, experiment 2).
Again a reduction of 26 to 28% was observed in the 3H/14C
ratios in poly(A)+ RNA isolated from cells treated with
analog 1.
Effects of analogs 1 and 2 and neplanocin A on rNTP
metabolism. After 6 h of incubation with or without 10 p.M
compound 1 or 2 or neplanocin A, cellular rNTPs (CTP,
UTP, ATP, and GTP) were analyzed. The rNTP pools in
L-929 cells were not disturbed by treatment with compound
Concentration (PlM, for AdoHcy/AdoM@t study)
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FIG. 4. Relationship between L-929 cell toxicity and AdoHcy/
AdoMet ratios in murine L-929 cells treated with various concen-
trations of analogs 1 and 2. L-929 cells were plated at 4.5 x 105 per
dish (30-mm diameter) and grown in Waymouth MB 752/1 medium
containing 2% calf serum. After 6 h of incubation, the cells were fed
with fresh medium without or with various concentrations of analog
1 (0) or 2 (0). After incubation for 72 h, the cells were harvested
and viable cells were determined by trypan blue staining. The data
are averages of experiments done in triplicate. AdoHcy/AdoMet
ratios (A, analog 1; A, analog 2) were determined after 24 h as
described in the legend to Fig. 2.
1 or 2 (Table 3). With neplanocin A treatment, however, all
rNTPs were decreased as follows relative to the control
values: CTP, 47%; UTP, 48%; ATP, 62%; GTP, 81%. An
ATP analog attributed to neplanocin A triphosphate was
detected at a concentration of approximately 573 pmol/106
cells.
DISCUSSION
AdoHcy hydrolase plays an important role in regulating
cellular levels of AdoHcy and subsequently regulating criti-
cal cellular AdoMet-dependent transmethylations (2, 27, 31).
Since AdoMet-dependent transmethylations are also critical
in the processing of viral mRNA (1) and thus virus replica-
tion, modulating the cellular levels of AdoHcy by inhibition
of cellular AdoHcy hydrolase has become an attractive
approach to the design of antiviral agents (7, 19, 24).
AdoHcy hydrolase inhibitors have been shown to be broad-
spectrum antiviral agents possessing activity against poxvi-
ruses (e.g., vaccinia virus), negative-strand RNA viruses
TABLE 1. Relationships among IC50s, ID50s, and changes in AdoHcy/AdoMet ratios in cells treated with analogs 1 and 2
At IC50 At ID50 Selectivity
AnalogIC50 AdoHcy AdoHcy/ AdoHcy Antiviral AdoHcy content AdoHcy/AdoMetAnalog ID5contntindexntat ID,0 minus ratio at ID50 minus(ILM)acontent AdoMet (Mb cnet AdoMet (IDs51C'(pmol/mg t. (pmol/mg ob ( /5050) AdoHcy content AdoHcy/AdoMet
of protein)' raio of protein)b rati at IC-O ratio at IC_o
1 0.28 100 0.15 17 825 1.34 61 725 1.19
2 0.95 125 0.19 56 950 1.30 59 825 1.11
Data taken from Fig. 3.
b Data taken from Fig. 4.
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TABLE 2. Effects of analog 1 on RNA methylation in vaccinia
virus-infected L-929 cells'
Sample and concn [3H]methio- ['4Cjuridine H/.C of Inhibition
(M) of analog 1 nine dpm dpm rat of methyH(expt no.) incorporation
Poly(A)+RNA
0 (1) 10,498 5,893 1.78 0
0 (2) 27,262 10,937 2.49 0
0.03 (1) 7,936 6,027 1.32 26
0.05 (2) 11,877 6,345 1.87 25
0.03 (1) 14,781 11,571 1.28 28
0.5 (2) 32,514 18,177 1.79 28
3 (1) 12,065 10,722 1.13 37
Total cytoplasmic
RNA
0 (1) 29,168 10,258 2.84 0
0.03 (1) 17,100 6,353 2.69 5
0.3 (1) 14,544 6,283 2.31 19
3 (1) 11,074 5,415 2.05 28
a L-929 cells in spinner culture with or without analog 1 were incubated for
18 h as described in Materials and Methods. The cells were infected with
vaccinia virus (multiplicity of infection, 15) and then treated with cyclohexi-
mide. After 1 h of incubation, adenosine and guanosine were simultaneously
added and 1 h later the cells were pulse-labeled with [methyl-3H]methionine
(10 ,uCi/ml) and [14C]uridine (0.5 ,Ci/ml). After 3 h of labeling the infected
cells were harvested and total cRNA and poly(A)+ RNA were isolated as
described in Materials and Methods. Small samples of RNA (100 ±l1) contain-
ing greater than 5,000 dpm of 14C radioactivity which were obtained by the
guanidine thiocyanate method and the oilgo(dT)-cellulose affinity chromatog-
raphy method were applied to DE-81 paper disks and washed with 5%
Na2HPO4 five times (5 ml per disk) and with distilled water twice, and the
radioactivity was counted. To ensure reproducibility, experiment 2 was
performed on another day by the same method but with different concentra-
tions of analog 1.
(e.g., the paramyxoviruses parainfluenza virus and measles
virus and the rhabdoviruses rabies virus and vesicular sto-
matitis virus), and double-stranded RNA viruses (reovirus
and rotavirus) (7). In contrast, herpes viruses and positive-
strand RNA viruses (the picornaviruses enterovirus and
rhinovirus and togavirus) are virtually resistant to the com-
pounds (7).
For viruses that replicate within the cytoplasm (e.g.,
vaccinia virus), it has been proposed that inhibition of
AdoHcy hydrolase and the subsequent elevation in intracel-
lular AdoHcy cause inhibition of viral mRNA methyltrans-
ferases which are responsible for methylating the terminal
guanosine residue (m7G) and the penultimate nucleoside
(Nm) in the mRNA cap (3, 18). This undermethylation is
thought to lead to inefficient association of viral mRNA with
ribosomes and, thus, reduced viral protein synthesis (3, 18).
AdoHcy inhibitors also exhibit antiviral activity against
influenza virus, a negative-strand RNA virus which repli-
cates its genome within infected cell nuclei (7). In influenza
virus, the viral mRNA is methylated by cellular enzymes
rather than viral enzymes (26). Ransohoff et al. (28) have
recently shown that inhibition of influenza virus replication
is due at least in part to impaired recognition of undermeth-
ylated viral mRNA cap structures by the influenza virus
polymerase complex. These results are consistent with the
findings in viral nucleocapsids that mRNAs possessing the
cap 1 (m7GpppNm) structure are 14-fold more active in
priming than those with a cap 0 (m7GpppN) structure (5).
These data suggest that the susceptibility of a virus to an
AdoHcy hydrolase inhibitor would depend ultimately on the
susceptibility of the viral (or cellular) enzyme(s) which
methylates the viral mRNA to inhibition by AdoHcy.
A potential disadvantage of selecting AdoHcy hydrolase
as a target for the design of antiviral agents is the fact that
AdoHcy hydrolase is a cellular enzyme. Thus, inhibition of
this cellular enzyme perturbs the cellular metabolism of
AdoHcy and homocysteine (32). Since cellular AdoMet-
dependent methyltransferases like the viral enzymes are
susceptible to inhibition by AdoHcy and cellular AdoMet-
dependent methyltransferases are critical to cellular viability
(31), why is it possible to selectively inhibit virus replication
and not perturb host cell viability? Until recently, it has been
difficult to address this question because many AdoHcy
hydrolase inhibitors are multifunctional drugs having effects
on a variety of molecular targets. For example, neplanocin A
is a potent inhibitor of AdoHcy hydrolase (3, 23), but it is
also a substrate for adenosine kinase, resulting in the forma-
tion of nucleotide metabolites that can be converted to
S-neplanocylmethionine (9, 10, 14, 15, 20, 21). In addition,
neplanocin A also causes reduction in both the purine and
pyrimidine nucleotide pools (Table 3). The transformation of
neplanocin A to the corresponding carbocyclic nucleotide
and S-neplanocylmethionine contributes significantly to the
cytotoxic properties of this molecule (10, 14, 15, 21),
whereas the inhibitory effects of the drug on AdoHcy
hydrolase appear to mediate its antiviral effects (3, 6, 7, 17,
19).
Recently, specific inhibitors of AdoHcy hydrolase which
are devoid of substrate activity for adenosine kinase and
adenosine deaminase have been synthesized. These AdoHcy
inhibitors include the carbocyclic analogs of 3-deazaadeno-
sine (24), the 3-deaza derivative of neplanocin A (9, 11; B.
Keller, K. Hillgren, C. Tseng, V. Marquez, and R. Bor-
chardt, FASEB [Fed. Am. Soc. Exp. Biol.] J. 2:A1348,
1988) and trans-2',trans-3'-dihydroxycyclopent-4'-enyl de-
rivatives 1 and 2 (Fig. 1) of neplanocin A (4, 12, 13; Keller et
al., FASEB J.). With these specific AdoHcy hydrolase
inhibitors, it is possible to elucidate the molecular mecha-
TABLE 3. rNTPs in murine L-929 cells treated with compound 1 or 2 or neplanocin A
Avg ± SD rNTP content (pmol/106 cells)'
Treatment'
CTP UTP ATP NpcTP' GTP
None (control) 216 + 31 464 ± 44 1,885 ± 128 365 + 42
Compound 1 214 ± 8 437 ± 19 1,809 ± 96 389 ± 7
Compound 2 194 ± 8 389 ± 28 1,631 ± 92 334 ± 51
Neplanocin A 102 6 223 9 1,186 +16 573 ± 13 297 17
aEach compound was used at 10 ,uM.
b The values are averages of triplicate assays.
On the basis of the elution pattern reported by Saunders et al. (29), the peak eluting immediately after the ATP peak in neplanocin-treated cells was assumed
to be neplanocin A triphosphate (NpcTP).
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nisms which allow for selective inhibition of virus replication
and not perturbation of host cell viability.
As shown in this study, the anti-vaccinia virus activities of
analogs 1 and 2 in L-929 cells can be closely correlated with
the accumulation of intracellular AdoHcy, the increase in
the AdoHcy/AdoMet ratios, and the inhibition of methyla-
tion of cytoplasmic poly(A)+ mRNA. L-929 cells, which
normally maintain low intracellular levels of AdoHcy (ap-
proximately 50 pmol/mg of protein) and low ratios of
AdoHcy/AdoMet (approximately 0.05 to 0.1), are a condu-
cive environment for vaccinia virus replication. However,
slight elevations in the intracellular level of AdoHcy (to
approximately 100 to 125 pmol/mg of protein) and elevations
in the ratio of AdoHcy/AdoMet (to approximately 0.15 to
0.19) caused by inhibition of cellular AdoHcy hydrolase
create an unfavorable environment which suppresses vac-
cinia virus replication. At concentrations of compounds 1
and 2 which produce these slight elevations in intracellular
AdoHcy and the AdoHcy/AdoMet ratio, inhibition of meth-
ylation of poly(A)+ RNA also occurs. These results strongly
suggest that inhibition of virus replication produced by low
concentrations (0.03 to 3.0 p.M) of compounds 1 and 2 results
from inhibition of highly susceptible AdoMet-dependent
methyltransferases that are critical for virus replication. Our
working hypothesis is that the highly susceptible AdoMet-
dependent enzyme(s) is the viral mRNA methyltransferase
responsible for formation of the capped structure (19).
In contrast to the extreme susceptibility of virus replica-
tion to slight elevations in the intracellular level of AdoHcy
and the AdoHcy/AdoMet ratio, cellular viability is quite
tolerant to higher levels of this same cellular metabolite. For
example, cellular toxicity was observed at intracellular
AdoHcy levels of approximately 825 to 950 pmol/mg of
protein and AdoHcy/AdoMet ratios of approximately 1.3.
The exact mechanism responsible for the cellular toxicity at
high concentrations (10 to 100 ,uM) of compounds 1 and 2 has
yet to be determined. This toxicity could result from inhibi-
tion of critical cellular AdoMet-dependent methyltrans-
ferases or general disruption of cellular AdoHcy-homocys-
teine homeostasis (32). Both mechanisms are being
examined in our laboratory.
Previously, our laboratory (12) reported that the levels of
antiviral effectiveness (ID5J1C50 ratios) of analogs 1 and 2
were 61 and 59, respectively. The data reported in this study
make it possible to define a therapeutic index for these
compounds based on a comparison of the AdoHcy cellular
levels at the ID50s and IC50s. These data show that with a
specific inhibitor of AdoHcy hydrolase, cellular toxicity
occurs only when intracellular concentrations of AdoHcy
are elevated seven to eight times above those needed to
inhibit virus replication.
Since cells are able to regulate intracellular levels of
AdoHcy in part by releasing the metabolite into the extra-
cellular medium (32), we were not surprised to see the
differences between the therapeutic index calculated on the
basis of the 1D50/1C50 ratio (approximately 60) and the
therapeutic index calculated by measuring the intracellular
levels of AdoHcy at the IC50s and ID50s (approximately 7 to
8).
In summary, the data reported in this paper show that
virus replication can be inhibited with only slightly elevated
levels of intracellular AdoHcy, whereas host cell toxicity is
produced at intracellular concentrations of AdoHcy which
are seven to eight times higher.
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